Trial Profile
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b When Added to Standard of Care Anticoagulation Therapy in Subjects With Acute Submassive Pulmonary Embolism
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 1040 (Primary) ; Enoxaparin sodium
- Indications Pulmonary embolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 11 May 2023 Results evaluating the tolerability and to explore the efficacy of DS-1040 in patients with acute PE, published in the Journal of Thrombosis and Haemostasis
- 08 Aug 2019 Status changed from recruiting to completed.
- 18 Jan 2019 Planned number of patients changed from 150 to 137.